Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Jul 9. doi: 10.1038/s41591-018-0095-6. [Epub ahead of print]

PMID:
29988124
2.

Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy.

Kather JN, Berghoff AS, Ferber D, Suarez-Carmona M, Reyes-Aldasoro CC, Valous NA, Rojas-Moraleda R, Jäger D, Halama N.

Oncoimmunology. 2018 Mar 29;7(7):e1444412. doi: 10.1080/2162402X.2018.1444412. eCollection 2018.

3.

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study.

Cortellini A, Porzio G, Masel EK, Berghoff AS, Knotzer B, Parisi A, Pavese F, Ficorella C, Verna L.

Palliat Support Care. 2018 May 24:1-5. doi: 10.1017/S1478951518000238. [Epub ahead of print]

PMID:
29792235
4.

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.

Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G.

Histopathology. 2018 May 9. doi: 10.1111/his.13646. [Epub ahead of print]

PMID:
29742291
5.

Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.

Wolpert F, Weller M, Berghoff AS, Rushing E, Füreder LM, Petyt G, Leske H, Andratschke N, Regli L, Neidert MC, Stupp R, Stahel R, Dummer R, Frauenfelder T, Roth P, Reyns N, Kaufmann PA, Preusser M, Le Rhun E.

Eur J Cancer. 2018 Jun;96:64-72. doi: 10.1016/j.ejca.2018.03.010. Epub 2018 Apr 17.

PMID:
29677642
6.

Anti-angiogenic therapies in brain metastases.

Berghoff AS, Preusser M.

Memo. 2018;11(1):14-17. doi: 10.1007/s12254-018-0384-2. Epub 2018 Feb 2. Review.

7.

Toward Precision Medicine in Brain Metastases.

Berghoff AS, Brastianos PK.

Semin Neurol. 2018 Feb;38(1):95-103. doi: 10.1055/s-0038-1627469. Epub 2018 Mar 16.

PMID:
29548056
8.

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.

PMID:
29477100
9.

Role of the blood-brain barrier in metastatic disease of the central nervous system.

Berghoff AS, Preusser M.

Handb Clin Neurol. 2018;149:57-66. doi: 10.1016/B978-0-12-811161-1.00004-9.

PMID:
29307361
10.

Educational video: the role of PD-L1 in the local tumour microenvironment.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2017 Feb 1;1(6):e000137. doi: 10.1136/esmoopen-2016-000137. eCollection 2016.

11.

CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology.

Preusser M, Berghoff AS, Thallinger C, Zielinski C.

ESMO Open. 2017 Jun 8;2(2):e000194. doi: 10.1136/esmoopen-2017-000194. eCollection 2017.

12.

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M.

Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.

PMID:
28531337
13.

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.

Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.

J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.

14.

Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12707. Epub 2017 May 10.

PMID:
28488812
15.

Targeted Therapies for Melanoma Brain Metastases.

Berghoff AS, Preusser M.

Curr Treat Options Neurol. 2017 Apr;19(4):13. doi: 10.1007/s11940-017-0449-2. Review.

16.

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A.

Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.

17.

Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma.

Berghoff AS, Kresl P, Bienkowski M, Koelsche C, Rajky U, Hainfellner JA, Preusser M.

Clin Neuropathol. 2017 Mar/Apr;36 (2017)(2):56-59. doi: 10.5414/NP300993.

PMID:
28128724
18.

Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.

PMID:
28096493
19.

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.

Eur Radiol. 2017 Aug;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6. Epub 2017 Jan 3.

20.

Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2016 Apr 12;1(3):e000056. eCollection 2016.

21.

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.

ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016.

22.

Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M.

J Neurooncol. 2016 Oct;130(1):19-29. Epub 2016 Jul 19.

PMID:
27436101
23.

In search of a target: PD-1 and PD-L1 profiling across glioma types.

Berghoff AS, Preusser M.

Neuro Oncol. 2016 Oct;18(10):1331-2. doi: 10.1093/neuonc/now162. Epub 2016 Aug 17. No abstract available.

24.

Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.

Osswald M, Blaes J, Liao Y, Solecki G, Gömmel M, Berghoff AS, Salphati L, Wallin JJ, Phillips HS, Wick W, Winkler F.

Clin Cancer Res. 2016 Dec 15;22(24):6078-6087. Epub 2016 Aug 12.

25.

Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.

Schweiger T, Berghoff AS, Glogner C, Glueck O, Rajky O, Traxler D, Birner P, Preusser M, Klepetko W, Hoetzenecker K.

Clin Exp Metastasis. 2016 Oct;33(7):727-39. doi: 10.1007/s10585-016-9813-y. Epub 2016 Jul 23.

26.

Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.

Berghoff AS, Venur VA, Preusser M, Ahluwalia MS.

Am Soc Clin Oncol Educ Book. 2016;35:e116-22. doi: 10.14694/EDBK_100005. Review.

27.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

28.

A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports.

Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H, Dressler A, Gnant M, Zielinski C, Bartsch R.

Clin J Oncol Nurs. 2016 Apr;20(2):175-80. doi: 10.1188/16.CJON.175-180.

PMID:
26991711
29.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M.

Oncoimmunology. 2015 Jun 9;5(1):e1057388. eCollection 2016.

30.

Genetic variants associated with colorectal brain metastases susceptibility and survival.

Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22.

PMID:
26689941
31.

Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.

Tschandl P, Berghoff AS, Preusser M, Pammer J, Pehamberger H, Kittler H.

Br J Dermatol. 2016 Feb;174(2):364-70. doi: 10.1111/bjd.14323. Epub 2016 Jan 9.

PMID:
26613644
32.

The PERS(2) ON score for systemic assessment of symptomatology in palliative care: a pilot study.

Masel EK, Berghoff AS, Schur S, Maehr B, Schrank B, Simanek R, Preusser M, Marosi C, Watzke HH.

Eur J Cancer Care (Engl). 2016 Jul;25(4):544-50. doi: 10.1111/ecc.12419. Epub 2015 Nov 12.

PMID:
26564404
33.

Brain tumour cells interconnect to a functional and resistant network.

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gömmel M, Pauli M, Liao Y, Häring P, Pusch S, Herl V, Steinhäuser C, Krunic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F.

Nature. 2015 Dec 3;528(7580):93-8. doi: 10.1038/nature16071. Epub 2015 Nov 4.

PMID:
26536111
34.

Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?

Preusser M, Berghoff AS, Wick W, Weller M.

Clin Neuropathol. 2015 Nov-Dec;34(6):313-21. Review.

35.

Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit.

Masel EK, Berghoff AS, Mladen A, Schur S, Maehr B, Kirchhoff M, Simanek R, Bauer M, Watzke HH, Amering M.

Palliat Support Care. 2016 Jun;14(3):250-8. doi: 10.1017/S1478951515000899. Epub 2015 Oct 8.

PMID:
26447347
36.

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, Weller M, Preusser M.

Neuro Oncol. 2016 Mar;18(3):401-7. doi: 10.1093/neuonc/nov183. Epub 2015 Sep 9.

37.

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M.

Clin Exp Metastasis. 2015 Oct;32(7):729-37. doi: 10.1007/s10585-015-9740-3. Epub 2015 Aug 25.

PMID:
26303828
38.

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions.

Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M.

Clin Neuropathol. 2015 Sep-Oct;34(5):250-7. Review.

39.

Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.

Ilhan-Mutlu A, Siehs C, Berghoff AS, Ricken G, Widhalm G, Wagner L, Preusser M.

Tumour Biol. 2016 Jan;37(1):1173-82. doi: 10.1007/s13277-015-3790-7. Epub 2015 Aug 16.

PMID:
26277786
40.

The future of targeted therapies for brain metastases.

Berghoff AS, Preusser M.

Future Oncol. 2015;11(16):2315-27. doi: 10.2217/fon.15.127. Review.

PMID:
26260810
41.

Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.

Preusser M, Berghoff AS, Koller R, Zielinski CC, Hainfellner JA, Liebmann-Reindl S, Popitsch N, Geier CB, Streubel B, Birner P.

Eur J Cancer. 2015 Sep;51(13):1803-11. doi: 10.1016/j.ejca.2015.06.107. Epub 2015 Jul 8.

PMID:
26164066
42.

The inflammatory microenvironment in brain metastases: potential treatment target?

Berghoff AS, Preusser M.

Chin Clin Oncol. 2015 Jun;4(2):21. doi: 10.3978/j.issn.2304-3865.2015.06.03. Review.

43.

Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.

Schiefer AI, Mesteri I, Berghoff AS, Haitel A, Schmidinger M, Preusser M, Birner P.

Histopathology. 2015 Dec;67(6):799-805. doi: 10.1111/his.12709. Epub 2015 Jun 7.

PMID:
25847631
44.

Atypical sporadic CJD-MM phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease.

Berghoff AS, Trummert A, Unterberger U, Ströbel T, Hortobágyi T, Kovacs GG.

Neuropathology. 2015 Aug;35(4):336-42. doi: 10.1111/neup.12192. Epub 2015 Mar 18.

PMID:
25783686
45.

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.

46.

Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.

Bergen ES, Berghoff AS, Rudas M, Preusser M, Bartsch R.

Anticancer Drugs. 2015 Jun;26(5):579-81. doi: 10.1097/CAD.0000000000000217.

PMID:
25714248
47.

Assessing MGMT methylation status and its current impact on treatment in glioblastoma.

Berghoff AS, Hainfellner JA, Marosi C, Preusser M.

CNS Oncol. 2015;4(1):47-52. doi: 10.2217/cns.14.50. Review.

PMID:
25586425
48.

Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.

Bojic M, Berghoff AS, Troch M, Agis H, Sperr WR, Widhalm G, Wöhrer A, Kalhs P, Preusser M, Rabitsch W.

Eur J Haematol. 2015 Jul;95(1):75-82. doi: 10.1111/ejh.12482. Epub 2015 Mar 23. Review.

PMID:
25546348
49.

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W.

Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.

50.

Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.

Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Höller C, Preusser M.

Histopathology. 2015 Jan;66(2):289-99. doi: 10.1111/his.12537. Epub 2014 Nov 10.

PMID:
25314639

Supplemental Content

Loading ...
Support Center